{
    "body": "List the diseases that can be treated using Vedolizumab.", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23046232", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21157649", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24067534", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23018007", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24918648", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23980911", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25105240", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23964933", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23964932", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23695427", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25110260", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22147460", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24160948", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24300858", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23295705", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19509315", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24246983", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22113039", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25186623", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24985716", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23083349", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23314806", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25294262", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25360311", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20594130", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24160949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24899819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25526490", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22762276", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23591599", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23394379", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23419117", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23718288", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23723689", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24479980", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25502899"
    ], 
    "ideal_answer": [
        "Ulcerative colitis and Crohn's disease are inflammatory bowel diseases that have been successfully treated with Vedolizumab, a gut-selective, anti-inflammatory monoclonal antibody."
    ], 
    "exact_answer": [
        [
            "Ulcerative colitis"
        ], 
        [
            "Crohn's disease"
        ]
    ], 
    "type": "list", 
    "id": "5508685b4b2a315d4100000a", 
    "snippets": [
        {
            "offsetInBeginSection": 240, 
            "offsetInEndSection": 411, 
            "text": "A new gut-specific monoclonal antibody, vedolizumab, has been shown to be effective in inflammatory bowel disease, and in continued trials no patients have developed PML. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24300858", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 594, 
            "offsetInEndSection": 746, 
            "text": "Finally, several studies were presented on new drugs with new therapeutic targets, such as vedolizumab, in the treatment of inflammatory bowel disease. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24160949", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 737, 
            "offsetInEndSection": 1045, 
            "text": "We review the role of vedolizumab, a humanized antibody against the \u03b14\u03b27 - integrin, in both ulcerative colitis (UC) and Crohn's disease (CD). Results from clinical trials show that vedolizumab is effective in the induction and maintenance of remission in active CD and UC and has a very good safety profile.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23980911", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 69, 
            "text": "Vedolizumab as induction and maintenance therapy for Crohn's disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964933", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1895, 
            "offsetInEndSection": 2239, 
            "text": "NCLUSIONS: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964933", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 72, 
            "text": "Vedolizumab as induction and maintenance therapy for ulcerative colitis.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964932", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1937, 
            "offsetInEndSection": 2054, 
            "text": "CONCLUSIONS: Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964932", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 75, 
            "text": "New and emerging treatments for ulcerative colitis: a focus on vedolizumab.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23723689", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 537, 
            "offsetInEndSection": 611, 
            "text": " This article reviews the emerging data on the use of vedolizumab for UC. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23723689", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1502, 
            "offsetInEndSection": 1596, 
            "text": " Newer treatments such as vedolizumab and tofacitinib may represent valuable future therapies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23718288", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 980, 
            "offsetInEndSection": 1166, 
            "text": "SUMMARY: New therapeutic targets in IBD patients who failed anti-TNF-\u03b1 therapy are urgently required, and tofacitinib, vedolizumab and ustekinumab appear to be the most promising drugs. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23695427", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 165, 
            "text": "BACKGROUND: Vedolizumab, a gut-selective, anti-inflammatory monoclonal antibody, has shown preliminary efficacy in ulcerative colitis (UC) and Crohn's disease (CD). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23591599", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1455, 
            "offsetInEndSection": 1709, 
            "text": "CONCLUSION: Vedolizumab every 8 weeks for up to 78 weeks had an adverse event profile similar to that previously observed. Mean disease activity indices (partial Mayo score and Crohn's Disease Activity Index score) improved with all 3 doses investigated.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23591599", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 484, 
            "offsetInEndSection": 812, 
            "text": "The new drugs discussed here are those that disturb lymphocyte homing to the gut (natalizumab, vedolizumab and anti-mucosal addressin cellular adhesion molecule); one that blocks interleukin (IL)-12 as well as the IL-23/T helper 17 (Th17) axis (ustekinumab) and one that blocks the signaling of multiple cytokines (tofacitinib).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23419117", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 33, 
            "text": "Vedolizumab  for Crohn's disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394379", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 396, 
            "offsetInEndSection": 851, 
            "text": "AREAS COVERED: This review discusses the potential role of vedolizumab, a humanised monoclonal antibody that selectively blocks lymphocyte trafficking to the gut, for the treatment of CD. All randomised placebo-controlled trials that evaluated vedolizumab for the treatment of CD were reviewed and safety and efficacy data evaluated. EXPERT OPINION: Vedolizumab is an effective and well-tolerated drug that is an important advance for the treatment of CD.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23394379", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1202, 
            "offsetInEndSection": 1510, 
            "text": "Treatment strategies that appear particularly appealing include selective anti-integrin therapy with vedolizumab (anti-\u03b14\u03b27), etrolizumab (anti-\u03b27 antibody) and PF-00547,659 (anti-MAdCAM-1 antibody), anti-interleukin 12/23p40 therapy with ustekinumab and Janus kinase 1, 2 and 3 inhibition with toafacitinib.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295705", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 447, 
            "offsetInEndSection": 933, 
            "text": "We discuss a number of them with specific focus on vedolizumab, a monoclonal antibody directed against the alpha4beta7 integrin on lymphocytes, ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, and tofacitinib, a small molecule targeting Janus-activated kinase. Most likely, these three agents will find their way to the market and offer significant therapeutic alternatives for the management of Crohn's disease and/or ulcerative colitis.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23314806", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 316, 
            "offsetInEndSection": 565, 
            "text": "Natalizumab, vedolizumab, alicaforsen AJM300, rhuMAb \u03b27, CCX282-B, and PF-00547,659 are few of monoclonal antibodies that have shown high promise in trials with the potential for more attractive benefit:risk ratio than currently available therapies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23083349", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 72, 
            "text": "Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046232", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 781, 
            "offsetInEndSection": 1060, 
            "text": "Here, we discuss the current treatment options available for patients with Crohn's disease or ulcerative colitis, the history of CAM inhibitors, the current state of development of vedolizumab and its future role in inflammatory bowel disease, if approved by regulatory agencies.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23046232", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 294, 
            "offsetInEndSection": 725, 
            "text": "Biological agents will probably be used earlier and more widely; new information on levels of biological agents, mucosal healing and new comparative studies will also allow these agents to be used in a more precise and personalized way. In addition to infliximab, adalimumab, natalizumab and certolizumab, other biological agents will be employed; among the first of these to be used will be ustekinumab, golimumab and vedolizumab.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23018007", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 637, 
            "offsetInEndSection": 826, 
            "text": "Several antibodies exist which constitute selection adhesion molecule inhibitors, including Natalizumab, MLN-0002 (Vedolizumab) and ISIS 2302 (Alicaforsen) will be discussed in this review.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22762276", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 111, 
            "text": "Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22147460", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 128, 
            "text": "BACKGROUND: Vedolizumab is a gut-selective biologic that has shown efficacy in ulcerative colitis (UC) and Crohn's disease (CD).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22147460", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 641, 
            "offsetInEndSection": 955, 
            "text": "They are anti CD4+ T cell cytokine including interleukin (IL)-12/23 and IL-17 blockers, selective anti-adhesion molecule known as natalizumab, vedolizumab and alicaforsen, T-cell proliferation inhibitor, anti-inflammatory cytokine, immune stimulator, growth factor, and mitogen-activated protein kinase inhibitor. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22113039", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 125, 
            "text": "Vedolizumab, a humanized mAb against the \u03b14\u03b27 integrin for the potential treatment of ulcerative colitis and Crohn's disease.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21157649", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1050, 
            "offsetInEndSection": 1458, 
            "text": "Data from phase II clinical trials of vedolizumab demonstrated efficacy with an attractive safety profile, especially in ulcerative colitis. Large phase III, multicenter trials in both ulcerative colitis and Crohn's disease will provide valuable data for the ongoing development of vedolizumab, which might evolve as a new anti-inflammatory treatment option for the management of therapy-refractory patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21157649", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 821, 
            "offsetInEndSection": 1036, 
            "text": "The development of a new specific molecule, vedolizumab, is currently under investigation in a large clinical trial. This novel specific anti-integrin drug seems to hold promise in the treatment of gut inflammation.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20594130", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 162, 
            "text": "The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509315", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 1694, 
            "offsetInEndSection": 1932, 
            "text": "These pharmacologic properties of vedolizumab, in conjunction with the gastrointestinal tropism of alpha(4)beta(7) integrin function, may ultimately confer an improved risk-to-benefit profile for patients with inflammatory bowel diseases.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509315", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1102, 
            "offsetInEndSection": 1332, 
            "text": "In the Crohn's disease study that included maintenance treatment, vedolizumab was significantly more effective at 52\u00a0weeks than placebo in both endpoints (clinical remission was the only primary endpoint in the maintenance study)", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25502899", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1663, 
            "offsetInEndSection": 1817, 
            "text": "Vedolizumab is a useful addition to the treatment options available for patients with moderately to severely active ulcerative colitis and Crohn's disease", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25502899", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1866, 
            "offsetInEndSection": 2197, 
            "text": "Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolizumab (rather than switching to placebo) were more likely to be in remission at week 52", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23964933", 
            "endSection": "abstract"
        }
    ]
}